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Extranodal connective tissue invasion and the
expression of desmosomal glycoprotein I in squamous
cell carcinoma of the oesophagus
S Natsugoe, J Mueller, F Kijima, K Aridome, M Shimada, K Shirao, C Kusano, M Baba, H Yoshinaka,
T Fukumoto and T Aikou
First Department of Surgery, Kagoshima University School of Medicine, Kagoshima 890, Japan
Summary We investigated extranodal connective tissue involvement (ECTI) in 39 patients with oesophageal carcinoma. Both the primary
tumour and ECTI were immunohistochemically examined using the monoclonal antibody 32-2B for desmosomal glycoprotein 1 (DG1).
Connective tissue carcinoma deposits were identified as cells within small lymph nodes, as lymphatic or venous vessel invasion or as
widespread invasion beyond the capsule of metastatic lymph nodes. These histological findings were present in at least one area in 20 of 39
patients (51.3%). DG1 immunostaining intensity by tumour was graded as DG1(++), DG1(+) or DG1(-). DG1(+) or DG1(-) primary tumours
demonstrated lymph node metastases and ECTI more frequently than DG1(++) tumours (P<0.05). Among 17 patients in whom DG1
immunohistochemistry was performed on ECTI, there were three DG1(++), five DG1(+) and nine DG1(-) patients. The DG1 expression of
ECTI was equal to or less intense than the primary tumour. These results indicate that reduction or loss of DG1 expression may promote ECTI
and lymph node metastases. One should be aware of the potential for ECTI in oesophageal carcinomas. In the future, adjuvanttherapy may
be advisable for some oesophageal carcinomas based on the phenotype of individual cancer cells, including expression of DG1.
Keywords: oesophageal cancer; extranodal connective tissue invasion; lymph node metastasis; desmosomal protein; cell adhesion
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The prognosis ofapatient withcarcinoma oftheoesophagus is poor
compared with that ofpatients with carcinomas ofother areas ofthe
digestive tract. Although theprognosis ofpatients with oesophageal
carcinoma has been improved by the use of extended lymph node
dissections (Siewert and Roder, 1992; Akiyama et al, 1994, Baba et
al, 1994), the incidence of recurrence is still high (Sugimachi et al,
1983; Chan et al, 1986; Natsugoe et al, 1994). Even if metastatic
lymph nodes are removed surgically, some patients will have
locoregional recurrence. Wehavepreviously reported (Yoshinaka et
al, 1991) that, when the resected lymph nodes were examined in
detail, perinodal invasion (cancer cells in the connective tissue
within a 2-mm zone surrounding the lymph node) was observed in
29 of73 patients (40%) and that the prognosis ofthese patients was
poorer than that ofpatients without this finding.
In the present study, we histologically examined extranodal
connective tissue involvement (ECTI) by oesophageal carcinoma
which we defined as tumour cells present in connective tissue at a
distance of more than 2 mm from the lymph node. Immuno-
histochemical studies, using the monoclonal antibody 32-2B to
desmosomal glycoprotein 1 (DG1) were performed. Desmosomes
are transmembrane structures with elements composed of various
glycoproteins, notably desmoglein and desmocollin, both of which
have recently been identified as members of the large family of
cadherins (Goodwin et al, 1990; Wheeler et al, 1991). The desmo-
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somal glycoprotein is a transmembrane molecule present in a wide
variety of epithelia. The 32-2B antibody reacts reliably with
epithelia andepithelial tumours in fixed, paraffin-embedded sections
(Vilela et al, 1987). Recently, Vilela et al (1995) reported that this
antibody recognized the cytoplasmic domains of both desmoglein
1 and desmoglein 3. The epidermal isoforms desmoglein 1 and
desmoglein 3 are restricted to certain specialized, mostly stratified
squamous, epithelia (Schafer et al, 1994). There have been some
studies of DG1 expression using the antibody 32-2B against transi-
tional cell carcinoma of the bladder (Conn et al, 1990), oral squa-
mous cell carcinoma (Imai et al, 1991; Harada et al, 1992) and
oesophageal squamous cell carcinoma (Natsugoe et al, 1995a).
The purpose of this study was to examine ECTI in the
oesophageal carcinoma and to compare it with the immunohisto-
chemical expression ofDG1.
PATIENTS AND METHODS
Patients
Thirty-nine patients with carcinoma of the oesophagus who had
undergone treatment at the First Department of Surgery,
Kagoshima University Hospital, were enrolled in this study forthe
period April 1992 to December 1993. Twenty-seven patients
underwent oesophagectomy combined with extensive dissection
of cervical, mediastinal and abdominal lymph nodes. Twelve
patients did not have a cervical lymph node dissection because of
advanced age or illness. The ages ofthe patients ranged from45 to
75 years (mean 62.9 years); there were 38 men and one woman.
None of the patients received radiation therapy or chemotherapy
before surgical treatment.
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Figure 1 (A) Cancer metastasis to a very small lymph node less than 2 mm in diameter (arrow, cancercells) (x40). (B) Lymphatic invasion into the connective
tissues (arrow, cancer cells; L, lymphatic vessel) (xl00). (C) Venous invasion into the connective tissues (arrow, cancer cells; V, vein) (x 100). (D) Widespread
invasion into connective tissues beyond the capsule of the metastatic lymph node (arrow, cancercells) (x100)
Post-operative radiation therapy or chemotherapy was given to
12 patients. All patients were followed up after discharge as
follows: a radiographic examination was done every 1-3 months,
computerized tomography every 3-6 months and ultrasonography
every 6 months. Bronchoscopic and endoscopic examination was
performed when necessary. We classified the types of carcinoma
recurrence as: (1) locoregional recurrence including the neigh-
bouring oesophageal bed and regional lymph nodes; (2)
haematogenous recurrence; and (3) mixed recurrence. Follow-up
data after surgery were available for all patients with a median
follow-up period of 10 months (range 1-24 months).
Based on the TNM classification of the International Union
Against Cancer (1987), the 39 patients were divided into ten
patients with Ti tumours, four patients with T2 tumours, 15
patients with T3 tumours and ten patients with T4 tumours. One
tumour was located in the upper one-third of the oesophagus, 24
tumours in the middle one-third and 14 tumours in the lower one-
third. Pathologically, all the tumours were squamous cell carci-
noma (11 well-differentiated, 19 moderately differentiated and
nine poorly differentiated).
Lymph node metastases were present in 26 of 39 of the cases
(66.7%). All of the Ml category tumours were due to distant
lymph node metastases. The number of resected nodes per patient
ranged from 16 to 107, with a median of 60 and the number of
lymph node metastases ranged from 0 to 54, with a mean ofeight.
Table 1 Relationship between ECTI and TNM pathological classification
ECTI- absent ECTI present
(n= 19) (n= 20) P-value
pT < 0.05
Ti 8 2
T2 3 1
T3 5 10
T4 3 7
pN < 0.01
NO 11 2
Ni 8 18
pM NS
MO 16 11
Mi 3 9
Stage < 0.05
7 1
IIA 3 1
IIB 3 1
III 3 8
IV 3 9
NS, not significant.
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Figure 2 Immunoreactive DG1 expression in normal oesophageal epithelial
cells. Normal epithelial cells strongly expressed DG1
Preparation of histological sections
Before this study, as part of the routine histological examination
following surgery, lymph nodes were macroscopically isolated
individually from the resection specimen along with approxi-
mately 2 mm of surrounding tissue. These lymph nodes were
labelled according to the areas that corresponded to the areas
designated by the Japanese Society for Esophageal Disease
(JSED) (1992). In this study, after the lymph nodes had been
macroscopically isolated, the residual connective tissue around the
excised lymph nodes was separated and classified in the same
fashion as the lymph nodes for histological examination. Very
small lymph nodes less than 2 mm in diameter, which could not be
macroscopically separated from surrounding connective tissues,
were also included in this study. Areas of connective tissue
surrounding primary tumours which macroscopically invaded the
para-oesophageal tissues were excluded from this study.
The tissues for study were fixed in 10% formalin and embedded
in paraffin. Serial 4-jim thick sections of the connective tissue
were prepared at three different levels, divided into three nearly
equal parts: upper, middle and lower. Tissue sections were
mounted on glass slides and stained with haematoxylin and eosin
(HE). A total of 1881 histological sections were prepared for
microscopic examination.
Immunohistochemical staining
The tissue sections were deparaffinized with xylene, dehydrated
with 98% ethanol and stained using an avidin-biotin-immunoper-
oxidase technique (ABC method). To block endogenous peroxidase
activity, the sections were immersed in a 0.3% hydrogen peroxi-
dase-methanol solution for 30 min and then washed with phos-
phate-buffered saline (PBS; pH 7.2) three times for 5 min each.
The sections were first incubated with mouse serum diluted
100-fold with PBS for 30 min at room temperature. After washing
with PBS, the sections were incubated at 4°C overnight with the
monoclonal antibody 32-2B for desmosomal glycoprotein 1
(Sanbio, USA) diluted 20-fold in 1% bovine serum albumin in
PBS. After washing with PBS, the specimens were incubated with
biotinylated rabbit anti-mouse IgG (Vector Laboratories, USA) for
30 min at room temperature. After washing with PBS, avidin-
conjugated peroxidase (Vector Laboratories, USA) was added, and
the incubation was continued for 60 min. The chromogen was
developed with 0.01% diaminobenzidine, and the sections were
counterstained with Mayer's haematoxylin and then coverslipped
using glycerol gelatin.
Immunohistochemical evaluation
The intensity and pattern ofDGl staining in the carcinoma cells of
both theprimary tumourandconnective tissues were interpreted as
follows: DG1(++), cells with strong staining (i.e. the same as that
of normal epithelium); DG1(+), cells with weaker staining inten-
sity than that of normal epithelium or some cells with the same as
that of normal epithelium, but others with weaker staining; and
DG1(-), cells without staining.
Statistical evaluation
The data obtained were statistically compared using a chi-square
test, with a P-value ofless than 0.05 considered to be significant.
Clinicopathological data vs ECTI
Histological examination of the connective tissues revealed
tumour in the following morphological patterns: (1) very small
lymph node less than 2 mm in diameter which could not be sepa-
rated macroscopically from surrounding connective tissues; (2)
lymphatic invasion; (3) venous invasion; and (4) widespread inva-
sion ofthe connective tissues with cancer cells infiltrating beyond
the capsule ofmetastatic lymph nodes (Figure 1). At least one area
ofECTI was present in 20 of 39 patients (51.3%) and 43 regional
connective tissue samples according to classification of code
number by JSED (1992).
The relationship between ECTI and TNM stage is summarized
in Table 1. Of the 25 patients with T3 or T4 tumours, ECTI was
present in 17. However, ECTI was also found in two often patients
with Tl tumours. Two of thirteen patients without lymph node
metastases (NO) had ECTI. ECTI was present in five of eight
patients who had between one and four positive nodes, in four of
six patients who had five and nine positive nodes and in 9 of 12
patients who had ten or more positive nodes.
DG1 expression vs clinicopathological findings
Normal squamous epithelial cells strongly expressed DG1 protein
at cell-cell boundaries (Figure 2). Of the 39 primary tumours
examined, 14 (35.9%) tumours were strongly positive for
desmoglein 1 [DGI(++)], 15 (38.5%) tumours were weakly posi-
tive fordesmoglein 1 [DG1(+)], and ten (25.6%) were negative for
desmoglein 1 [DGI(-)] (Figure 3). Lymph node metastases were
observed in five (35.7%) of the DGI(++) tumours, 12 (80.0%) of
the DG1(+) tumours and nine (90.0%) of the desmoglein 1 nega-
tive tumours. The difference between the percentage of DG1(++)
tumours and weak or negative tumours was statistically significant
(P < 0.05) (Table 2) with respect to metastases.
A similar relationship between the ECTI and DG1 expression in
primary tumour was seen, with the ECTI rates in DG1(++),
DGI(+) and DGI(-) being 21.4%, (3/14) 60% (9/15) and 80%
(8/10) respectively. There were statistically significant differences
between the DG1(++) and DG1(+) groups (P < 0.05), and between
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Figure 3 Immunohistochemical expression of DG1 in a primary oesophageal tumour. (A) DG1(++) tumour. All of the tumour cells strongly express DG1. (B)
DG1 (+) tumour. DG1 expression in all tumour cells was weaker than in normal epithelial cells. (C) DG1(+) tumour. Some tumour cells expressed DG1 strongly,
but others weakly. (D) DG1(-) tumour. No DG1 expression was seen in the tumour cells
Table 2 DG1 expression of primary tumour with or without lymph node
metastasis
DG1 expression (%)
(++) (+) (-) Total
LN negative 9 (64.3) 3 (20.0) 1 (10.0) 13 (33.3)
LN positive 5 (35.7) 12 (80.0) 9 (90.0) 26 (66.7)
*P< 0.05.
Table 3 DG1 expression of primary tumour with or without ECTI
DG1 expression (%)
(++) (+) (-) Total
ECTI negative 11 (78.6) 6 (40.0) 2 (20.0) 19 (48.7)
ECTI positive 3 (21.4) 9 (60.0) 8 (80.0) 20 (51.3)
*P< 0.05. **P< 0.01.
the DG1(++) and DG1(-) groups (P < 0.01) (Table 3) with respect
to ECTI.
The immunohistochemical expression of DG1 in the tumour
cells ofthe foci ofECTI was studied in the same manner as in the
primary tumour. However, the small foci of cancer cells disap-
peared in the additional sections prepared for immunohistochem-
istry in 8 of 43 lesions in the 20 patients with ECTI seen on HE
staining. The remaining 35 lesions of 17 patients were evaluated
immunohistochemically. There was no discrepancy among
multiple foci of ECTI in terms of DG1 expression from the same
patients. Of these 17 patients, the numbers of lesions with
DG1(++), DGI(+) and DG1(-) tumour cells were three, five and
nine respectively (Figure 4). When DG1 expression between the
primary tumours and ECTI was compared, all ofthe three primary
tumours with DG1(++) and ECTI also had DG1(++) in their ECTI
foci. In five of seven primary tumours with DG1(+) and ECTI, the
ECTI also had DG1(+); and all seven primary tumours with
DG1(-) and ECTI also had ECTI foci that were DG1(-) (Table 4).
No ECTI focus was observed in which the DG1(++) expression of
the primary tumourchanged to DG1(+) or DGl(-) in the ECTI, or
in which DG1(+) or DG1(-) expression in the primary tumour
changed to DG1(++) in the ECTI focus (Table 4).
Clinically, 2 of the 35 patients in this series died ofpost-opera-
tive complications, and 17 patients had recurrent disease after
British Journal ofCancer (1997) 75(6), 892-897 0 Cancer Research Campaign 1997896 S Natsugoe etal
A B
Figure 4 Immunohistochemical expression of DG1 in the ECTI (A) DG1 (++) tumour. (B) DG1(-) tumour
Table 4 Relationship between DG1 expression and recurrence
Case no. DG1 expression DG1 expression Mode of
in primary tumour in ECTI recurrence
1 - - L
2 - - L
3 - - L
4 - - M
5 - - H
6 - - P
7 - _
8 + - L
9 + _
10 + + L
11 + + L
12 + + L
13 + + M
14 + +
15 ++ ++ P
16 ++ ++
17 ++ ++
L, locoregional recurrence; H, haematogenous recurrence; M, mixed
recurrence; P, post-operative hospital death.
surgery. Recurrent legions were locoregional in nine patients,
haematogeneous in four patients and mixed in four patients.
Among the patients in whom DG1 expression of ECTI was
immunohistochemically studied, recurrence was found in 10 of 15
patients, excluding the two patients who died of post-operative
complications. These ten patients had either DGI(-) or DGI(+)
expression in the tumour cells of both the primary lesion and the
ECTI foci. Concerning the mode ofrecurrence, locoregional recur-
rence was the predominant pattern in seven of these ten patients
(Table 4).
DISCUSSION
Lymph node metastasis is one of the most important prognostic
factors for determining the outcome of patients with oesophageal
cancer. Even if a complete lymph node dissection is performed and
no lymph node metastases are found, some patients still suffer from
recurrent disease. Occult metastases have been found in detailed
histological examinations by means of additional tissue sections.
The incidence ofoccult lymph node metastases have been reported
to range from 2% to 33% (Kingsley etal, 1985; International Breast
Cancer Study Group, 1990; Natsugoe et al, 1991). Although many
reports concerned with lymph node metastases have been
published, there are few reports on ECTI. One must also pay special
attention to connective tissues, because cancer cells move through
the lymphatics and veins of the connective tissues. Fifty-one per
cent of the 39 patients in this study had tumour involving the para-
oesophageal connective tissues. Almost all of the lesions consisted
of small numbers of cancer cells. These lesions could be detected
neither macroscopically nor by routine histological examination.
Desmosomes act as intercellular junctions which provide sites
of strong adhesion between epithelial cells. According to electron
microscopic study, a decrease in the number of desmosomes in
invasive carcinoma may contribute to reduction in cell adhesion
and to metastatic potential (Arloy et al, 1981). We have also previ-
ously reported a decrease in the number of desmosomes in
oesophageal cancer cells compared with normal epithelium, as
shown by electron microscopy (Aikou et al, 1993). However, elec-
tron microscopic studies are necessarily based on small samples of
tissue. The use of immunohistochemistry enables the study of
much larger areas of a tumour and allows a more accurate impres-
sion ofthe overall distribution and number ofdesmosomes.
When the relationship between DGI expression of the primary
tumour and the presence of lymph node metastases was observed,
lymph node metastases were found to occur more frequently in
tumours with weak or negative expression ofDG1 than in tumours
which strongly expressed DG1. As we also saw in our study,
Harada et al (1992) reported that the immunohistochemical DG1
expression of the tumour in metastatic lymph nodes of oral squa-
mous cell carcinoma was as weak as that ofthe primary tumour. A
tumour with reduction or loss of DG1 expression may be more
likely to metastasize to lymph nodes.
Furthermore, in our study, the frequency of ECTI was lower in
tumours that strongly expressed DGI. On the other hand, ECTI
frequently occurred in tumours in which DG1 expression was
reduced or lost. DGI expression in the tumour cells of the ECTI
foci was unchanged or reduced in all patients comapred with the
DG1 expression of the corresponding primary tumour. These find-
ings suggest that partial or complete loss of DGI expression by
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cancer cells may promote ECTI as well as lymph node metastases.
In other words, once the desmosomal attachment structure becomes
impaired, the risk of metastases increases. However, three patients
had tumours with strong DGl expression in both the primary
tumour and in the ECTI foci. It is possible that, in these tumours,
the DG1 recognized by the 32-2B antibody is non-functional.
The frequency of recurrence in patients with weak or negative
expression of DGI tumours was high despite the short follow-up
period. The mode of recurrence of these patients was most
commonly locoregional. These results fit with the clinical progres-
sion of these tumours as these patients also had both lymph node
metastases and ECTI.
The persistence of tumour cells in the form ofresidual deposits
ofECTI not removed by surgery treatment may be responsible for
these recurrences. This would be an argument in favour of the use
of various forms of adjuvant therapy (Kelsen et al, 1990 Orringer
et al, 1990). A targeted drug delivery system might be a useful
means for obtaining high concentrations of anti-cancer agents in
occult lymph node metastases or ECTI (Hagiwara et al, 1988;
Natsugoe et al, 1995b).
In this study, we demonstrated a high frequency of ECTI in
oesophageal cancer which appears to be a factor in the tumour
recurrence. The relative lack of expression of DG1 may identify
those oesophageal tumours which are more likely to metastasize in
the form of nodal metastases or ECTI. In the future, adjuvant
therapy may be an important tool in eradicating tumour cells in the
form of occulat nodal metastases and ECTI that cannot be
removed surgically.
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